{"id":"penehyclidine-inhalation","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Penehyclidine acts as a selective M1 and M3 muscarinic receptor antagonist, reducing parasympathetic-mediated bronchoconstriction and excessive mucus production in the airways. When administered via inhalation, it provides rapid local effects on airway smooth muscle and secretory glands, making it useful for managing acute respiratory conditions characterized by bronchospasm and hypersecretion.","oneSentence":"Penehyclidine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce airway secretions and bronchospasm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:58.547Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute airway obstruction and bronchospasm"},{"name":"Excessive airway secretions in respiratory conditions"}]},"trialDetails":[{"nctId":"NCT06624696","phase":"PHASE4","title":"Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":"Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics","enrollment":204},{"nctId":"NCT03868709","phase":"PHASE4","title":"Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2019-03-12","conditions":"Postoperative Complications, Long-term Outcome","enrollment":864},{"nctId":"NCT02644876","phase":"PHASE4","title":"Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2015-09-01","conditions":"Postoperative Complications","enrollment":864},{"nctId":"NCT02202239","phase":"PHASE4","title":"Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2014-09","conditions":"Hemodynamics, Oxidative Stress, Anesthesia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Penehyclidine Hydrochloride for Injection (Changtuoning)"],"phase":"marketed","status":"active","brandName":"Penehyclidine inhalation","genericName":"Penehyclidine inhalation","companyName":"Peking University First Hospital","companyId":"peking-university-first-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Penehyclidine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce airway secretions and bronchospasm. Used for Acute airway obstruction and bronchospasm, Organophosphate or nerve agent poisoning (anticholinergic effects).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}